Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer

References

• Wong MCS, Lao XQ, Ho K-F, Goggins WB, Tse SLA. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep. 2017;7(1):14300. doi:10.1038/s41598-017-14513-729085026
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19. doi:10.1007/978-3-319-24223-1_126667336
   PubMed Web of Science ®Google Scholar
• Paracha N, Abdulla A, MacGilchrist KS. Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients. Health Qual Life Outcomes. 2018;16(1):179. doi:10.1186/s12955-018-0994-830208899
   PubMedGoogle Scholar
• Wang T, Hossann M, Reinl HM, et al. In vitro characterization of phosphatidylglyceroglycerol-based thermosensitive liposomes with encapsulated 1H MR T1-shortening gadodiamide. Contrast Media Mol Imaging. 2008;3(1):19–26. doi:10.1002/cmmi.22618330933
   PubMedGoogle Scholar
• Bunn PA Jr, Soriano A, Johnson G, Heasley L. New therapeutic strategies for lung cancer: biology and molecular biology come of age. Chest. 2000;117(Suppl 4):163S–168S. doi:10.1378/chest.117.4_suppl_1.163S10777473
   PubMedGoogle Scholar
• Sun YW, Xu J, Zhou J, Liu W-J. Targeted drugs for systemic therapy of lung cancer with brain metastases. Oncotarget. 2017;9(4):5459–5472. doi:10.18632/oncotarget.2361629435193
   PubMedGoogle Scholar
• Zhang J, Qiao L, Liang N, et al. Vasculogenic mimicry and tumor metastasis. J BUON. 2016;21(3):533–541.27569069
   PubMed Web of Science ®Google Scholar
• Owattanapanich W, Owattanapanich N, Kungwankiattichai S, Ungprasert P, Ruchutrakool T. Efficacy and toxicity of idarubicin versus high-dose daunorubicin for induction chemotherapy in adult acute myeloid leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2018;18:814–821.e3. doi:10.1016/j.clml.2018.08.00830241991
   PubMed Web of Science ®Google Scholar
• Xu PY, Kankala RK, Pan YJ, Yuan H, Wang S-B, Chen A-Z. Overcoming multidrug resistance through inhalable siRNA nanoparticles-decorated porous microparticles based on supercritical fluid technology. Int J Nanomedicine. 2018;13:4685–4698. doi:10.2147/IJN.S16939930154654
   PubMed Web of Science ®Google Scholar
• Yousefinejad S, Honarasa F, Montaseri H. Linear solvent structure-polymer solubility and solvation energy relationships to study conductive polymer/carbon nanotube composite solutions. RSC Adv. 2015;5:42266. doi:10.1039/C4RA14244F
   Web of Science ®Google Scholar
• Kankala RK, Liu CG, Chen AZ. Overcoming multidrug resistance through the synergistic effects of hierarchical pH-sensitive, ROS-generating nanoreactors. ACS Biomater Sci Eng. 2017;3(10):2431–2442. doi:10.1021/acsbiomaterials.7b00569
   PubMed Web of Science ®Google Scholar
• Ying X, Wen H, Lu WL, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release. 2010;141(2):183–192. doi:10.1016/j.jconrel.2009.09.02019799948
   PubMed Web of Science ®Google Scholar
• Kim JS, Shin DH, Kim JS. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells. J Control Release. 2017;269:245–257. doi:10.1016/j.jconrel.2017.11.02629162480
   PubMed Web of Science ®Google Scholar
• Li L, Hou J, Liu X, et al. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials. 2014;35(12):3840–3850. doi:10.1016/j.biomaterials.2014.01.01924486214
   PubMed Web of Science ®Google Scholar
• Xiang B, Jia X-L, Qi J-L, et al. Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system. Int J Nanomedicine. 2017;12:2385–2405. doi:10.2147/IJN.S12957428405163
   PubMed Web of Science ®Google Scholar
• Majumder P, Bhunia S, Chaudhuri A. A lipid-based cell penetrating nano-assembly for RNAi-mediated anti-angiogenic cancer therapy. Chem Commun. 2018;54(12):1489–1492. doi:10.1039/C7CC08517F
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos-Sternberg B, D’Souza GGM. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci U S A. 2003;100(4):1972–1977. doi:10.1073/pnas.043590610012571356
   PubMed Web of Science ®Google Scholar
• Fischer R, Fotin-Mleczek M, Hufnagel H, Brock R. Break on through to the other side-biophysics and cell biology shed light on cell-penetrating peptides. Chembiochem. 2005;6(12):2126–2142. doi:10.1002/cbic.20050004416254940
   PubMedGoogle Scholar
• Henriques ST, Melo MN, Castanho MA. Cell-penetrating peptides and antimicrobial peptides: how different are they? Biochem J. 2006;399(1):1–7. doi:10.1042/BJ2006110016956326
   PubMedGoogle Scholar
• Yuan M, Qiu Y, Zhang L, Gao H, He Q. Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma. Drug Deliv. 2016;23(4):1171–1183. doi:10.3109/10717544.2015.104052726036724
   PubMed Web of Science ®Google Scholar
• Boussoufi F, Navarro Gallón S, Chang R, Webster TJ. Synthesis and study of cell-penetrating peptide-modified gold nanoparticles. Int J Nanomedicine. 2018;13:6199–6205. doi:10.2147/IJN.S16872030349244
   PubMed Web of Science ®Google Scholar
• Lin W, Xie X, Yang Y, et al. Thermosensitive magnetic liposomes with doxorubicin cell-penetrating peptides conjugate for enhanced and targeted cancer therapy. Drug Deliv. 2016;23(9):3436–3443. doi:10.1080/10717544.2016.118998327193383
   PubMed Web of Science ®Google Scholar
• Cai D, Gao W, He B, et al. Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy. Biomaterials. 2014;35(7):2283–2294. doi:10.1016/j.biomaterials.2013.11.08824360410
   PubMed Web of Science ®Google Scholar
• Lakkadwala S, Singh J. Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model. Colloids Surf B Biointerfaces. 2018;173:27–35. doi:10.1016/j.colsurfb.2018.09.04730261346
   PubMedGoogle Scholar
• Watkins CL, Brennan P, Fegan C, et al. Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD. J Control Release. 2009;140(3):237–244. doi:10.1016/j.jconrel.2009.04.02819409429
   PubMed Web of Science ®Google Scholar
• Lin S, Wang D, Yang D, Yao J, Tong Y, Chen J. Characterization of steroidal saponins in crude extract from Dioscorea nipponica Makino by liquid chromatography tandem multi-stage mass spectrometry. Anal Chim Acta. 2007;599(1):98–106. doi:10.1016/j.aca.2007.07.07017765069
   PubMedGoogle Scholar
• Sun W, Tu G, Zhang Y. A new steroidal saponin from Dioscorea zingiberensis Wright. Nat Prod Res. 2003;17(4):287–292. doi:10.1080/147864103100013699712822909
   PubMed Web of Science ®Google Scholar
• Tao X, Yin L, Xu L, Peng J. Dioscin: a diverse acting natural compound with therapeutic potential in metabolic diseases, cancer, inflammation and infections. Pharmacol Res. 2018;137:259–269. doi:10.1016/j.phrs.2018.09.02230315966
   PubMed Web of Science ®Google Scholar
• Lim WC, Kim H, Kim YJ, et al. Dioscin suppresses TGF-beta1-induced epithelial-mesenchymal transition and suppresses A549 lung cancer migration and invasion. Bioorg Med Chem Lett. 2017;27(15):3342–3348. doi:10.1016/j.bmcl.2017.06.01428610976
   PubMedGoogle Scholar
• Aumsuwan P, Khan SI, Khan IA, et al. The anticancer potential of steroidal saponin, dioscin, isolated from wild yam (Dioscorea villosa) root extract in invasive human breast cancer cell line MDA-MB-231 in vitro. Arch Biochem Biophys. 2016;591:98–110. doi:10.1016/j.abb.2015.12.00126682631
   PubMedGoogle Scholar
• Kou Y, Ji L, Wang H, et al. Connexin 43 upregulation by dioscin inhibits melanoma progression via suppressing malignancy and inducing M1 polarization. Int J Cancer. 2017;141(8):1690–1703. doi:10.1002/ijc.3087228677156
   PubMedGoogle Scholar
• Si L, Zheng L, Xu L, et al. Dioscin suppresses human laryngeal cancer cells growth via induction of cell-cycle arrest and MAPK-mediated mitochondrial-derived apoptosis and inhibition of tumor invasion. Eur J Pharmacol. 2016;774:105–117. doi:10.1016/j.ejphar.2016.02.00926849940
   PubMed Web of Science ®Google Scholar
• Liu S, Zhang SM, Ju RJ, et al. Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma. Eur J Pharm Sci. 2017;106:185–197. doi:10.1016/j.ejps.2017.06.00228583810
   PubMed Web of Science ®Google Scholar
• Song XL, Ju RJ, Xiao Y, et al. Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer. Int J Nanomedicine. 2017;12:7433–7451. doi:10.2147/IJN.S14178729066893
   PubMed Web of Science ®Google Scholar
• Ju RJ, Cheng L, Peng XM, et al. Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer. Artif Cells Nanomed Biotechnol. 2018;46:616–628. doi:10.1080/21691401.2018.1433187.
   Web of Science ®Google Scholar
• Yang J, Li W, Luo L, et al. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance. Biomaterials. 2018;182:145–156. doi:10.1016/j.biomaterials.2018.08.00430121013
   PubMed Web of Science ®Google Scholar
• Li C, Hu J, Li W, Song G, Shen J. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment. Biomater Sci. 2016;5(1):77–88. doi:10.1039/c6bm00449k27822577
   PubMedGoogle Scholar
• Pumerantz AS. PEGylated liposomal vancomycin: a glimmer of hope for improving treatment outcomes in MRSA pneumonia. Recent Pat Antiinfect Drug Discov. 2012;7(3):205–212.22742394
   PubMedGoogle Scholar
• Luo Q, Yang B, Tao W, et al. ATB0,+ transporter-mediated targeting delivery to human lung cancer cells via aspartate-modified docetaxel-loading stealth liposomes. Biomater Sci. 2017;5(2):295–304. doi:10.1039/c6bm00788k27991616
   PubMed Web of Science ®Google Scholar
• Anabousi S, Laue M, Lehr C-M, Bakowsky U, Ehrhardt C. Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. Eur J Pharm Biopharm. 2005;60(2):295–303. doi:10.1016/j.ejpb.2004.12.00915939240
   PubMed Web of Science ®Google Scholar
• Thakur C, Rapp UR, Rudel T. Cysts mark the early stage of metastatic tumor development in non-small cell lung cancer. Oncotarget. 2017;9(5):6518–6535. doi:10.18632/oncotarget.2378529464089
   PubMedGoogle Scholar
• Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155(3):739–752. doi:10.1016/S0002-9440(10)65173-510487832
   PubMed Web of Science ®Google Scholar
• Seftor RE, Hess AR, Seftor EA, et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol. 2012;181(4):1115–1125. doi:10.1016/j.ajpath.2012.07.01322944600
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437. doi:10.1038/nm.339424202395
   PubMed Web of Science ®Google Scholar
• Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med. 2013;19(11):1450–1464. doi:10.1038/nm.339124202397
   PubMed Web of Science ®Google Scholar
• Schroeder A, Heller DA, Winslow MM, et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer. 2011;12(1):39–50. doi:10.1038/nrc318022193407
   PubMed Web of Science ®Google Scholar
• Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25(1):9–34. doi:10.1007/s10555-006-7886-916680569
   PubMed Web of Science ®Google Scholar
• Cappelli HC, Kanugula AK, Adapala RK, et al. Mechanosensitive TRPV4 channels stabilize VE-cadherin junctions to regulate tumor vascular integrity and metastasis. Cancer Lett. 2018;442:15–20. doi:10.1016/j.canlet.2018.07.04230401632
   PubMedGoogle Scholar
• Ko H, So Y, Jeon H, et al. TGF-β1-induced epithelial–mesenchymal transition and acetylation of Smad2 and Smad3 are negatively regulated by EGCG in human A549 lung cancer cells. Cancer Lett. 2013;335(1):205–213. doi:10.1016/j.canlet.2013.02.01823419524
   PubMed Web of Science ®Google Scholar
• Li R, Shi Y, Zhao S, et al. NF-kappaB signaling and integrin-beta1 inhibition attenuates osteosarcoma metastasis via increased cell apoptosis. Int J Biol Macromol. 2018;123:1035–1043. doi:10.1016/j.ijbiomac.2018.11.003.
   PubMedGoogle Scholar
• Lotfi K, Zackrisson AL, Peterson C. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance. Cancer Lett. 2002;178(2):141–149.11867198
   PubMed Web of Science ®Google Scholar